Clinical Trials Logo

Disorder of Transplanted Kidney clinical trials

View clinical trials related to Disorder of Transplanted Kidney.

Filter by:
  • None
  • Page 1

NCT ID: NCT02902120 Completed - Hepatitis C Clinical Trials

HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant

Start date: May 1, 2017
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether patients treated for chronic hepatitis C (HCV) with zepatier (grazoprevir/elbasvir) prior to kidney transplant will have a stronger immune response compared to patients treated after kidney transplant. 25 patients with chronic kidney disease (CKD) and HCV will be treated with zepatier and 25 kidney transplant recipients with chronic kidney disease will be treated with zepatier. Blood markers of immune function will be monitored in both groups to determine their response to therapy.

NCT ID: NCT02017990 Completed - Clinical trials for Disorder of Transplanted Kidney

Plasma Marine n-3 Polyunsaturated Fatty Acids and Patient and Graft Survival

Start date: October 1999
Phase: N/A
Study type: Observational

This study will evaluate the association between n-3 polyunsaturated fatty acids and patient and graft survival. The association between other fatty acids and mortality and graft loss endpoints will also be evaluated.

NCT ID: NCT01436747 Completed - Proteinuria Clinical Trials

Efficacy and Safety of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients

Start date: July 2012
Phase: Phase 3
Study type: Interventional

The study 'Safety and Efficacy of Paricalcitol for Reduction of Proteinuria in Kidney Transplant Recipients' is designed to assess the effects of paricalcitol in kidney transplant recipients with proteinuria. It is a single centre, randomized, placebo-controlled, double-blind clinical trial that tests the hypothesis that 24 weeks' treatment with paricalcitol compared to placebo will result in a decrease in urinary protein excretion in recipients of a kidney transplant at least three months after transplantation. Additionally, the effects of paricalcitol on albuminuria, estimated glomerular filtration rate, and blood pressure will be investigated.

NCT ID: NCT01353053 Recruiting - Clinical trials for Cytomegalovirus Infections

Comparison of Two Immunosuppressive Regimens in Kidney Transplant Recipients With Deceased Donors With the Aim of Preventing the Development of Fibrosis / Atrophy of Reducing the Incidence of Cytomegalovirus Infection

Start date: July 2010
Phase: N/A
Study type: Observational

The aim of this the study is to the assess whether the graft and patient survival, rejection rates and renal graft function after the first year will not differ between both study arms. The investigators will also the evaluate the reduction in the incidence of cytomegalovirus the and improvement of renal function of the everolimus after 1 year.

NCT ID: NCT01349595 Terminated - Clinical trials for Disorder of Transplanted Kidney

Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation

Start date: December 2011
Phase: Phase 2
Study type: Interventional

The purpose of this study is to see if treating patients who have high levels of donor specific alloantibodies post-transplant with bortezomib might prevent the development of transplant glomerulopathy and preserve allograft function.